Previous 10 | Next 10 |
Report documents ESG accomplishments and reflects commitment to corporate responsibility ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (AD...
Company to host webcast today at 9:00 a.m. EST ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignan...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, P...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced it will host a webca...
ADC Therapeutics to receive $30 million upfront payment, up to $205 million in milestones, and double-digit royalties based on net sales in Japan ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with i...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, P...
The following slide deck was published by ADC Therapeutics SA in conjunction with their 2021 Q3 earnings call. For further details see: ADC Therapeutics SA 2021 Q3 - Results - Earnings Call Presentation
Several presentations will highlight broad potential of CD19-targeted ADC ZYNLONTA ® (loncastuximab tesirine-lpyl) as a single agent and in combination for the treatment of non-Hodgkin lymphomas ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology comp...
Image source: The Motley Fool. ADC Therapeutics SA (NYSE: ADCT) Q3 2021 Earnings Call Nov 02, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: ADC Therapeutics SA (ADCT) Q3 2021 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Q3 2021 Earnings Conference Call November 02, 2021, 08:30 AM ET Company Participants Amanda Hamilton - Investor Relations Manager Christopher Martin - Co-Founder, CEO Jennifer Herron - Chief Commercial Officer & SVP Jennifer Creel - Chief Financial Officer Joe C...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...